Immunotherapy
From the Journals
New injectable gel can deliver immune cells directly to cancer tumors
The gel “is a really exciting step forward because it can change the delivery of these cells and expand this kind of treatment to other cancers...
Latest News
Adverse skin effects of cancer immunotherapy reviewed
“The desirable, immune-mediated oncologic response is often achieved at the cost of immune-related adverse events (irAEs) that may potentially...
From the Journals
Women at higher risk of serious adverse events from cancer therapy
As cancer treatment becomes increasingly individualized, “sex may be an important consideration.”
From the Journals
Review eyes nail unit toxicities secondary to targeted cancer therapy
Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies....
From the Journals
Hyperprogression on immunotherapy: When outcomes are much worse
News from the FDA/CDC
FDA panel votes against 2 cancer indications but backs 4 of 6
At a 3-day meeting, an FDA advisory group considered the accelerated approvals of six cancer indications for three immunotherapies.
News from the FDA/CDC
To stay: Two more cancer indications with ‘dangling approvals’
Conference Coverage
Allo-HSCT plus monoclonal antibody treatment can improve survival in patients with r/r B-ALL
Conference Coverage
Checkpoint inhibitor–induced rheumatic complications often arise late
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
From the Journals
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
A Dutch nationwide study in melanoma patients found relative safety of immune checkpoint inhibitors for grade 3 immune-related AEs but does not...
Clinical Insights
How should we evaluate the benefit of immunotherapy combinations?